WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation
Sponsor: |
Boston Scientific Corporation |
Enrolling: |
Male and Female Patients |
Clinic Visits: |
9 |
IRB Number: |
AAAT2212 |
U.S. Govt. ID: |
NCT04394546 |
Contact: |
Kate Dalton: 347-514-3366 / keb2114@cumc.columbia.edu |
This is a prospective, randomized, multi-center global investigational study. The primary objective is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs - drugs that inhibits clotting) in patients with Atrial Fibrillation (AF) - irregular heart rhythm caused by other things, such as high blood pressure or an overactive thyroid gland.
This study is closed
Investigator
Robert Sommer, MD
Do you have atrial fibrillation (AF)? |
Yes |
No |
Are you on anticoagulation for reasons other than AF-related stroke risk reduction? |
Yes |
No |
Have you had a transient ischemic attack (TIA) or Stroke? |
Yes |
No |
Have you had a patent foramen ovale (PFO)/ atrial septal defect (ASD) closed? |
Yes |
No |